ARTICLES https://doi.org/10.1038/s41591-021-01318-5 Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies 1,2,3,22 1,2,3,221,2,3,4 1,2,3 Delphine Planas, Timothée Bruel, Ludivine Grzelak, Florence Guivel-Benhassine, 1,2,3 1,2,35 1,2,3 Isabelle Staropoli, Françoise Porrot, Cyril Planchais, Julian Buchrieser, 1,2,3,4 1,2,3,46,7 6,78 Maaran Michael Rajah, Elodie Bishop, Mélanie Albert, Flora Donati, Matthieu Prot, 6,7 6,79 1010 Sylvie Behillil, Vincent Enouf, Marianne Maquart, Mounira Smati-Lafarge, Emmanuelle Varon, 11 1213 14,1516 Frédérique Schortgen, Layla Yahyaoui, Maria Gonzalez, Jérôme De Sèze, Hélène Péré, 16,17 188 19,209,21 David Veyer, Aymeric Sève, Etienne Simon-Lorière, Samira Fafi-Kremer, Karl Stefic, 5 186,7,23 18,23 Hugo Mouquet, Laurent Hocqueloux, Sylvie van der Werf, Thierry Prazuckand ᅒ 1,2,3,23 Olivier Schwartz Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants were first identified in the United Kingdom and South Africa, respectively, and have since spread to many countries. These variants harboring diverse mutations in the gene encoding the spike protein raise important concerns about their immune evasion potential. Here, we isolated infectious B.1.1.7 and B.1.351 strains from acutely infected individuals.
Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) B.1.1.7 and B.1.351 variants were first identified in the United Kingdom and South Africa, respectively, and have since spread to many countries. These variants harboring diverse mutations in the gene encoding the spike protein raise important concerns about their immune evasion potential. Here, we isolated infec tious B.1.1.7 and B.1.351 strains from acutely infected individuals. We examined sensitivity of the two variants to SARSCoV2 antibodies present in sera and nasal swabs from individuals infected with previously circulating strains or who were recently vaccinated, in comparison with a D614G reference virus. We utilized a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection. Sera from 58 convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G. In contrast, after 9 months, convalescent sera had a mean sixfold reduction in neutralizing titers, and 40% of the samples lacked any activity against B.1.351. Sera from 19 individuals vaccinated twice with Pfizer Cominarty, longitudinally tested up to 6 weeks after vaccination, were similarly potent against B.1.1.7 but less efficacious against B.1.351, when compared to D614G. Neutralizing titers increased after the second vaccine dose, but remained 14fold lower against B.1.351. In contrast, sera from convalescent or vaccinated individuals similarly bound the three spike proteins in a flow cytometrybased serological assay. Neutralizing antibodies were rarely detected in nasal swabs from vaccinees. Thus, fasterspreading SARSCoV2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels. Our results indicate that B1.351, but not B.1.1.7, may increase the risk of infection in immunized individuals.
ARS-CoV-2 varîans ave rapîdly emerged în umans and 1–5 îoSn advanage a e populaîon level. One o e îrs îdenîîed supplaned ancesral sraîns . Teîr proposed încreased raes o înerîndîvîdual ransmîssîon conerred a replîca-varîans încludes e D614G muaîon în e gene encodîng e spîke (S) proeîn, wîc enances vîral înecîvîy and sîs S pro-eîn conormaîon oward an angîoensîn-converîng enzyme 2 (ACE2)-bîndîng usîon-compeen sae, wîou sîgnîîcanly mod-1,6–8 îyîng sensîîvîy o anîbody neuralîzaîon . More recenly, novel varîans ave appeared în mulîple counrîes, wî combînaîons
o muaîons and deleîons în e recepor-bîndîng domaîn (RBD) and N-ermînal domaîn o S proeîn, as well as în oer proeîns. Te B.1.1.7 varîan emerged în e Unîed Kîngdom, e B.1.351 varîan (also ermed 501Y.V2) în Sou Arîca and e P.1 and 2,3,5,9–12 P.2 lîneages în Brazîl . Aloug dîsînc, e varîans sare common caracerîsîcs, încludîng known escape muaîons a were prevîously îdenîîed under anîbody pressure selecîon 2,3,13–17 în vîro . Some o e muaîons or deleîons were also îdenî-îed în îmmunocompromîsed îndîvîduals wî prolonged înecîous vîral seddîng and reaed wî convalescen plasma or S-proeîn
1 2 3 Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France. CNRS UMR 3569, Paris, France. Vaccine Research Institute, Créteil, 4 5 France. Université de Paris, Sorbonne Paris Cité, Paris, France. Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, 6 INSERM U1222, Paris, France. Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur CNRS UMR 3569, Université de Paris, Paris, 7 8 France. National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France. G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, 9 10 11 Paris, France. INSERM U1259, Université de Tours, Tours, France. CHI de Créteil, Service de Biologie Médicale, Créteil, France. CHI de Créteil, Service 12 13 de Réanimation, Créteil, France. CHI de Créteil, Service des Urgences, Créteil, France. CHU de Strasbourg, Service de Pathologie Professionnelle et 14 15 Médecine du Travail, Strasbourg, France. Centre d’investigation Clinique INSERM 1434, CHU Strasbourg, France. CHU de Strasbourg, Service de 16 Neurologie, Strasbourg, France. INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris 17 18 and Sorbonne Université, Paris, France. Hôpital Européen Georges Pompidou, Service de Virologie, Paris, France. CHR d’Orléans, Service de maladies 19 20 infectieuses, Orléans, France. CHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France. Université de Strasbourg, INSERM, IRM UMR_S 1109, 21 22 Strasbourg, France. CHRU de Tours, National Reference Center for HIV-Associated laboratory, Tours, France. These authors contributed equally: 23 Delphine Planas, Timothée Bruel. These authors jointly supervised this work: Sylvie van der Werf, Thierry Prazuck, Olivier Schwartz. ✉ e-mail:olivier.schwartz@pasteur.fr
NATuRE MEDICINE|www.nature.com/naturemedicine
ARTICLES
3,17–19 monoclonal anîbodîes , îndîcaîng a anîbody-escape mua-îons are seleced în vîvo. Te sensîîvîy o anîbody neuralîza-îon varîes wî e vîral varîan. B.1.1.7 seems o be more sensîîve o neuralîzaîon an B.1.351. Te RBD muaîon N501Y, wîc încreases aînîy o ACE2 and îs presen în B.1.1.7 and B.1.351 20 (re. ), does no împaîr on îs own pos-vaccîne serum neural-21 îzaîon . ï as been suggesed a e oer muaîons în B.1.1.7 22 do no resul în îmmune evasîon o lînear epîopes . Muaîons în e B.1.351 and P.1 sraîns, încludîng E484K and K417N/T, are o îg concern, sînce ey parly compromîse neuralîza-23–25 îon generaed by prevîous înecîon or vaccînaîon or may încrease îneren vîral îness. Te Pîzer Comînary (also ermed BNT162b2) vaccîne-elîcîed uman sera neuralîzes SARS-CoV-2 lîneage B.1.1.7 pseudovîrus, wî slîgly reduced îers în some 26,27 vaccînees, wen compared o e Wuan reerence sraîn . Te Moderna mRNA-1273 vaccîne also înduces neuralîzîng anîbodîes o SARS-CoV-2 varîans wî, owever, a îve- o en-old reduc-îon în eîcacy agaîns e B.1.351 S proeîn, wen compared o 27,28 pseudovîrus bearîng e D614G muaîon . Neuralîzaîon eîcacy as so ar mosly been assessed usîng vesîcular somaîs vîrus (VSV)-derîved or lenîvîrus-derîved pseu-dovîrus assays, or wî înecîous SARS-CoV-2 carryîng poîn muaîons în S proeîn. A recen repor usîng înecîous B.1.351 vîrus sowed a plasma samples rom sîx convalescen donors were srongly aenuaed agaîns îs sraîn, wî al-maxîmal înîbîory concenraîon (ïC50) values 6- o 200-old îger an 29 ancesral vîrus . ï îs us o umos împorance o use auenîc varîan sraîns în addîîon o pseudovîrus parîcles, sînce muaîons ousîde o e S proeîn may împac îneren vîral îness and/or sensîîvîy o anîbodîes. Here, we compared e sensîîvîy o ree auenîc SARS-CoV-2 sraîns, e preexîsîng D614G vîrus and e B.1.1.7 and B.1.351 varîans, o anîbody neuralîzaîon.
ResUlts Isolation and characterization of SARSCoV2 B.1.1.7 and B.1.351 variants.îsolaed e wo varîans rom nasal swabs We o îndîvîduals wî înecîon dîagnosed by quanîaîve PCR wî reverse ranscrîpîon (RT–qPCR) and sequence-dîagnosed înec-îon. Te vîruses were amplîîed by one o wo passages on Vero cells. Sequences o e ougrown vîruses conîrmed e îdenîy o B.1.1.7 and B.1.351 varîans. Vîral socks were îraed usîng S-Fuse 30 reporer cells . Tese cells are derîved rom a uman îmmoralîzed + lîne, ermed U2OS-ACE2 cells. Tey carry e GFP-splî comple-menaîon sysem, în wîc wo cells separaely produce al o e reporer proeîn, producîng GFP only upon usîon. Followîng înecîon, e cells produce S proeîn a eîr surace and use wî neîgborîng cells, generaîng a GFP sîgnal as soon as 6 aer înec-30+ îon (Fîg.1a). Te number o GFP cells correlaed wî e vîral înoculum (Fîg.1b). Neuralîzîng SARS-CoV-2 monoclonal anî-bodîes (mAbs) argeîng e RBD can be classîîed îno our maîn 31,32 caegorîes . Usîng e S-Fuse assay, we esed e sensîîvîy o e ree vîral sraîns o wo RBD anîbodîes, mAb102 and mAb48, derîved rom convalescen îndîvîduals. Te anîbodîes belong o e îrs caegory and ac by blockîng bîndîng o e ‘up’ conor-32 maîon o RBD o ACE2 (re. ). MAb102 eîcîenly and sîmîlarly −1 neuralîzed e ree vîral sraîns, wî an ïC50 o≃0.01µg ml −1 (Fîg.1c,d). MAb48 neuralîzed D614G (ïC50 o 0.1µg ml ) bu was înacîve agaîns B.1.1.7 and B.1.351 varîans (Fîg.1c,d). Tese resuls conîrm a e wo varîans can selecîvely dîsplay reduced sensîîvîy o ceraîn anîbodîes. O noe, e acîvîy o e mono-clonal anîbodîes was sîmîlar a dîeren vîral înocula, wîîn a + range o 50 o 200 GFP syncyîa per well (Fîg.1e), îndîcaîng a poenîal varîaîons în e number o îneced S-Fuse cells do no împac e calculaîon o ïC50. Tus, or urer sudîes, we seleced a mulîplîcîy o înecîon leadîng o abou 150 syncyîa per well or eac vîral sraîn.
NATURE MEDICINE
Sensitivity of D614G, B.1.1.7 and B.1.351 variants to sera from convalescent individuals.We assessed e neuralîzaîon abîlîy o sera rom convalescen îndîvîduals. We seleced samples rom 28 donors în a longîudînal coor o îndîvîduals wî SARS-CoV-2 rom e Frenc cîy o Orléans (Supplemenary Table 1). All îndî-vîduals were dîagnosed wî SARS-CoV-2 înecîon by RT–qPCR or serology and încludîng ose wo ad crîîcal, severe and mîld-o-moderae coronavîrus dîsease 2019 (COVïD-19). Tey were no vaccînaed. A oal o 25 îndîvîduals were sampled wîce: îrs, a a medîan o 89 d (range 77–105 d) pos onse o symp-oms (POS; 3-mon samples (M3)), and second, a a medîan o 179 d (range 168–197 d) POS (6-mon samples (M6). We încu-baed serîally dîlued sera wî D614G, B.1.1.7 or B.1.351 sraîns, + added e mîxure o S-Fuse cells, and scored e GFP cells aer overnîg înecîon. We en calculaed e medîan eecîve dose (ED50) or eac combînaîon o serum and vîrus. A represena-îve example wî e same donor îs depîced în Fîg.2a, and e resuls wî all donors appear în Fîg.2b. Te D614G and B.1.1.7 sraîns were sîmîlarly sensîîve o sera. A M3, e ED50values were 3 3 1.5×10 and 1×10 or D614G and B.1.1.7 varîans, respecîvely, 2 4 wî uge varîaîons beween îndîvîduals (rom 10 o 2×10 ), and e values dîd no srongly declîne a M6. As expeced, îndîvîdu-als wî crîîcal dîsease dîsplayed îger neuralîzîng acîvîîes an ose wî severe or mîld-o-moderae sympoms (Exended DaaFîg. 1). Agaîn, ere was no sîgnîîcan dîerence beween e wo vîral sraîns în eac caegory o sympoms. For B1.351, e neural-îzaîon îers were sîgnîîcanly decreased by îve and en-old a e wo îme poîns, wen compared wî D614G and B.1.1.7 sraîns (Fîg.2band Exended Daa Fîg. 1). We conîrmed ese resuls în sera rom 30 îndîvîduals rom anoer coor o RT–qPCR-conîrmed unvaccînaed eal-care workers rom Srasbourg Unîversîy Hospîal wo experîenced mîld 33,34 dîsease . Te samples were colleced a a laer îme poîn (M9), wî a medîan o 233 d (range 206–258 d) POS (Supplemenary Table 1).Overall, e neuralîzaîon acîvîy was lower (one represenaîve example îs sown în Fîg.2a and e resuls o all donors are avaîl-able în Fîg.2b). Tere was no sîgnîîcan dîerence în neuralîzaîon 2 beween D614G and B.1.1.7 sraîns, wî a sîmîlar ED50o 2×10 . ïn sarp conras, e neuralîzîng acîvîy agaîns B.1.351 was parîcu-larly low a îs lae îme poîn, wî a medîan ED50o 50, represen-îng a ourold decrease wen compared o D614G (Fîg.2b). We en arbîrarîly classîîed e îndîvîduals as neuralîzers (wî neuralîzîng anîbodîes deecable a e îrs serum dîluîon o 1:30) and non-neuralîzers, or e ree vîral sraîns and e wo coors (Fîg.2c). Mos îndîvîduals neuralîzed e ree sraîns a M3. Te racîon o neuralîzers sared o declîne a M6, a penomenon wîc was more marked or B.1.351. Te racîon o neuralîzers was îger în e second coor, wî 93% o îndîvîduals neural-îzîng eîer D614G or B.1.1.7 sraîns a M9. ïn conras, only 63% o îndîvîduals neuralîzed e B.1.351 sraîn (Fîg.2c).
Antibody binding to cells expressing D614G, B.1.1.7 and B.1.351 S proteins.We nex examîned e bîndîng capacîy o monoclonal anîbodîes and sera rom e convalescen îndîvîduals descrîbed above o S proeîns rom dîeren lîneages. To îs aîm, we adaped e low cyomery-based S-Flow assay, wîc we prevîously esab-lîsed o measure e levels o anîbodîes bîndîng o cells expressîng 35 e Wuan S proeîn . We ransîenly ranseced uman epîe-lîal HEK293T (reerred o as 293T) cells wî plasmîds expressîng e D614G, B.1.1.7 and B.1.351 S proeîns. Sîmîlar surace levels o e vîral proeîns were deeced wî mAb10, a non-neuralîzîng pan-coronavîrus anîbody argeîng a conserved epîope în e S2 domaîn and îsolaed rom a convalescen îndîvîdual (C. Plancaîs e al., unpublîsed daa; Fîg.3aSupplemenary Fîg. 1). and Moreover, e cells used wen coculîvaed wî ACE2-expressîng cells, îndîcaîng a e ree proeîns were uncîonal (daa no
NATuRE MEDICINE|www.nature.com/naturemedicine
0 10
+ GFP
Infection 18 h
b
D614G
B.1.1.7
150
200
NATURE MEDICINE
SFuse GFP1–10 GFP11
d 120
B.1.351
100
No. of syncytia 50
0
NATuRE MEDICINE|www.nature.com/naturemedicine
Sensitivity of D614G, B.1.1.7 and B.1.351 variants to sera from vaccine recipients. We nex asked weer vaccîne-elîcîed anî-bodîes înîbî înecîon by e dîeren varîans. ïn France, vaccî-naîon sared în January 2020 wî e Pîzer Comînary vaccîne.
–2 –1 10 10 –1 µg ml
mAb48 D614G B.1.1.7 B.1.351
40 Neutralization (%) 20
sown). mAb48 eîcîenly bound o D614G S proeîns, slîgly less poenly o B.1.1.7, and los all bîndîng acîvîy o B.1.351. Tereore, e escape o mAb48 neuralîzaîon by e wo varîans îs due o muaîons decreasîng or abrogaîng anîbody bîndîng o îs arge. mAb102 bound sîmîlarly o e ree S proeîns, în accor-dance wî îs cross-reacîve neuralîzîng acîvîy (Fîg.3a,b). Te N501Y muaîon enances RBD aînîy o ACE2, wen esed wî 20 recombînan proeîns and yeas surace dîsplay . Usîng low cyom-ery, we assessed by e bîndîng o a labeled soluble ACE2 proeîn o cells expressîng e dîeren S proeîns. We observed a dramaîc încrease în bîndîng o soluble ACE2 o B.1.1.7 and o a lesser exen o B.1.351, wîc bo carry e N501Y muaîon, wen compared o D614G (Fîg.3a,b). We nex esed our panel o sera rom convalescen îndîvîdu-als agaîns e dîeren S proeîns. Overall, e sera bound sîmî-larly o all ree S proeîns, even oug B.1.351 dîsplayed a slîg reducîon (saîsîcally sîgnîîcan a M6) în e mean luorescence înensîy (MFï) o bîndîng (Fîg.3c). We observed a global and slîg decrease în MFï a M9, compared o samples rom M3 and M6(Fîg.3c). Alogeer, ese resuls îndîcae a S proeîns rom B.1.351, and o a îger exen B.1.1.7, dîsplay încreased aînîy or ACE2 wîle escapîng bîndîng o some monoclonal anîbodîes and eîer o a lesser degree or no a all o polyclonal sera.
20
40
mAb102
60
80
100
e 120
0 10
20
60
40
100
80
120
mAb102
mAb48
mAb102
–2 –1 10 10 –1 µg ml
We us seleced 19 vaccîne recîpîens rom a coor o vaccînaed eal-care workers esablîsed în Orléans. Te caracerîsîcs o vaccînees are depîced în Supplemenary Table 2. Sera and nasal swabs were sampled a week 2 (17 îndîvîduals), week 3 (18 îndî-vîduals), week 4 (11 îndîvîduals; correspondîng o week 1 aer e second dose), week 5 (16 îndîvîduals; correspondîng o week 2 aer e second dose) and week 6 (15 îndîvîduals; correspondîng o week 3 aer e second dose), wî a medîan o 13, 19, 28, 34 and 41 d aer e îrs dose, respecîvely. Tîs allowed us o assess e early umoral response o vaccînaîon. We îrs analyzed 16 o 19 vaccîn-ees a were no prevîously îneced wî SARS-CoV-2, as assessed by e absence o preexîsîng S-proeîn and anî-nucleoproeîn (N) anîbodîes. A represenaîve example o e evoluîon o e neu-ralîzîng response în one vaccîne recîpîen a e our îme poîns îs depîced în Fîg.4a. ïn îs însance, e serum only neuralîzed D614G a week 2, wereas B.1.1.7 sared o be neuralîzed a week 3, aloug less eîcîenly an D614G. B.1.1.7 and D614G sraîns were sîmîlarly neuralîzed a week 4. Te anî-B.1.351 response was negaîve up o week 3, and became deecable a week 4, a a level lower an e wo oer vîruses. Te ED50 resuls rom sera o e 16 vaccîne recîpîens a e our îme poîns are presened în Fîg.4b, wereas e evoluîon o eîr neuralîzaîon îers over e 6 weeks aer vaccînaîon appears în Fîg.4c. We also arbîrarîly classîîed îndîvîduals as neuralîz-ers (wî neuralîzîng anîbodîes deecable a a serum dîluîon o 1:30) and non-neuralîzers, or e ree vîral sraîns (Fîg.4d).Two weeks aer vaccînaîon, anîbodîes neuralîzîng e D614G sraîn were deeced în sera rom 5 o 15 recîpîens (33%; wî an
0 –3 10
–3 –2 –1 10 10 10 –1 µg ml
0 –4 10
0 –3 10
0 10
1× 4× 8× Viral inoculum
ARTICLES
a
80
60
1× 4× 8×
100
c
Control
Fig. 1 |Effect of two SARS-CoV-2 monoclonal antibodies on D614G, B.1.1.7 and B1.351 strains.a, Principle of the S-Fuse reporter assay. S-Fuse cells, a mix of U20S-ACE2-GFP1–10 and U20S-ACE2-GFP11, were cocultured at a 1:1 ratio and infected with SARS-CoV-2. Cells fused upon infection and generated + a GFP signal. Infection was quantified by measuring the number of GFP syncytia at 18 h.b, Linearity of the assay with D614G (gray), B.1.1.7 (blue) and B.1.351 (green) strains. S-Fuse cells were exposed to serial dilutions of viral stocks and infection was quantified by high-content imaging.c, Representative images (from five independent experiments) of S-Fuse cells infected with D614G, B.1.1.7 and B1.351 strains in the presence or absence of two SARS-CoV-2 monoclonal antibodies (mAb48 and mAb102). Scale bar, 400µm.d, Dose-response analysis of the neutralization by mAb102 and mAb48 on the three viral strains.e, Neutralization of SARS-CoV-2 (B.1.1.7) by mAb102 at three viral inocula. Results are shown as the mean±standard deviation (s.d.) from four independent experiments.
NATuRE MEDICINE|www.nature.com/naturemedicine
îers încreased în mos o e recîpîens and were sîmîlar beween D614G and B.1.1.7. Tîers remaîned 14-old and 53-old lower agaîns B.1.351, wen compared o D614G and B.1.117, respecîvely (Fîg.4b,c). A week 3, 63%, 38% and 0% o e samples neuralîzed D614G, B.1.1.7 and B.1.351 sraîns, respecîvely (Fîg.4d). A week 6, 92% o e samples neuralîzed D614G and B.1.1.7, wereas 77% neuralîzed B.1.351 wî a low îer (Fîg.4d). Te S-Flow assay dem-onsraed e presence o anîbodîes bîndîng o e ree S proeîns
0
D614GB.1.1 .B7.1.351
0
1 2 3 10 10 10 Serum dilution
4 10
0
arbîrary resold o ED50>30 or neuralîzaîon posîîvîy; Fîg. 4b,d). Te îers were relaîvely modes a îs early îme poîn (ED50o 30). Tese low îers were less eîcîen agaîns B.1.1.7, wî 2 o 15 neuralîzers (13%), and were înacîve agaîns B.1.351 (Fîg.4b,c). A week 3, e neuralîzîng acîvîy încreased agaîns D614G and B.1.1.7. Tere was, owever, a reeold reducîon în e neural-îzaîon îers agaîns B.1.1.7 (Fîg.4b), wereas B.1.351 remaîned însensîîve. A e las îme poîn (week 3 aer e second dose),
60
80
0
1 2 3 10 10 10 Serum dilution
Neutralizer (ED > 30) 50
4 10
40 Neutralization (%) 20
100
60
1 2 3 10 10 10 Serum dilution
20
30
100
10 No. of convalescents
20
M9 POS
0
40
80
4 10
1 10
5 10
NATURE MEDICINE
Fig. 2 |Sensitivity of SARS-CoV-2 D614G, B.1.1.7 and B.1.351 variants to sera from convalescent individUals.a, Examples of neutralization curves with sera from two donors (D18 and D59). The first donor, from the Orléans cohort, was sequentially sampled at months 3 (M3) and 6 (M6; left and middle, respectively). The second donor, from the Strasbourg cohort, was sampled at month 9 (M9; right). Results are shown as the mean±s.d. from three independent experiments.b, ED50of neutralization of the three viral isolates. Sera from the Orléans cohort were sequentially sampled at M3 (n=28) and M6 (n=25; left and middle, respectively), and 30 sera from the Strasbourg cohort were sampled at M9 (right). Data are the mean from two to four independent experiments. The dotted line indicates the limit of detection (ED50=30). Two-sided Friedman test with Dunn’s test for multiple comparisons was performed between each viral strain at the different time points; **P<0.01, ***P<0.001, ****P<0.0001. M3: D614G versus B.1.351,P=0.0012; B.1.1.7 versus B.1.351,P=0.0012. M6: D614G versus B.1.351,P=0.0005; B.1.1.7 versus B.1.351,P<0.0001. M9: D614G versus B.1.351,P<0.0001; B.1.1.7 versus B.1.351,P<0.0001.c, Each individual was arbitrarily defined as a ‘neutralizer’ (blue) if neutralizing activity was detected at the first serum dilution (1:30) or ‘non-neutralizer’ (gray) if no activity was detected. The numbers indicate the percentage of neutralizers.
Fig. 3 |Antibody binding to cells expressing D614G, B.1.1.7 and B.1.351 S proteins.a, Binding of monoclonal antibodies or soluble ACE2. HEK293T cells were transiently transfected with plasmids expressing the D614G, B.1.1.7 and B.1.351 S proteins. After 24 h, cells were stained with SARS-CoV-2 antibody −1 mAb10 (a pan-coronavirus antibody), mAb48, mAb102 or soluble ACE2 (ACE2-biotin at 10μg ml revealed with fluorescent streptavidin) and analyzed by flow cytometry. One representative example of binding is shown.b, Titration binding curves of mAb48, mAb102 and ACE2 to the three S proteins. Data are the mean±s.d. of three independent experiments.c, Binding of the panel of 83 sera from 58 convalescent individuals. Sera were tested at a 1:300 dilution. Data are the mean of two independent experiments. Two-sided Friedman test with Dunn’s test for multiple comparisons was performed between each viral strain at the different time points, *P<0.05. M6: B.1.1.7 versus B.1.351,P=0.037.
all îme poîns (up o 6 weeks aer vaccînaîon; Exended DaaFîg. 2a,b). We also analyzed ree addîîonal vaccîne recîpîens wo were seroposîîve or anî-N a e îme o vaccînaîon, îndîca-îve o a prevîous înecîon. Two recîpîens were dîagnosed wî SARS-CoV-2 by PCR în Marc and Aprîl 2020 and experîenced a mîld dîsease. Te îrd recîpîen dîd no repor any prevîous sîgns remînîscen o COVïD-19. ïn ese ree îndîvîduals, e serum neuralîzîng îers were srîkîngly îg a week 2 aer e îrs dose 4 (ED50o abou 10 ; Exended Daa Fîg. 2c) and remaîned sîmîlarly îg a week 5 (daa no sown). Two o e ree vaccîne recîpîens wo were prevîously seroposîîve or SARS-CoV-2 dîsplayed a low neuralîzîng acîvîy în eîr nasal swabs, wen measured a week 2 aer e îrs dose (Exended Daa Fîg. 2d). Teîr nasal swabs neuralîzed D614G and B.1.117 sraîns sîmîlarly bu were înacîve agaîns B.1.351. As a conrol, we analyzed en pre-pandemîc naso-paryngeal swab specîmens (colleced by e Naîonal Reerence
a e dîeren samplîng îmes (Exended Daa Fîg. 2). Tereore, e Pîzer Comînary vaccîne generaed a neuralîzîng response a eîcîenly argeed D614G and B.1.1.7 wî a delay în e appear-ance o neuralîzîng anîbodîes o B.1.1.7 and B.1.351 relaîve o D614G. Te îers remaîned lower agaîns B.1.351, even în respond-ers. Te vaccîne dîsplays a proecîve eîcacy agaîns COVïD-19 as 36 soon as 2 weeks aer e îrs dose . Our resuls sugges a e low neuralîzîng îers (ED50o 50–100) în e sera may correspond o e observed proecîon agaîns severe dîsease.
Sensitivity of SARSCoV2 B.1.1.7 and B.1.351 variants to nasal swabs from vaccine recipients.Lîle îs known abou e levels and uncîon o vaccîne-elîcîed anîbodîes în mucosal samples. We us measured e neuralîzîng acîvîy and e levels o anîbodîes în nasal swabs rom e serîes o vaccîne recîpîens (Exended DaaFîg. 2). We dîd no deec any anîvîral eec în ese samples a
NATuRE MEDICINE|www.nature.com/naturemedicine
NATuRE MEDICINE|www.nature.com/naturemedicine
D9
W4 after vaccination (W1 after second dose)
2 10
1 10
0 10
3 10
4 10
1 2 3 10 10 10 Serum dilution
D614BG.1.1 .B7.1.351
W4 after vaccination W6 after vaccination (W1 after second dose) (W3 aftersecond dose) * 5 5 10 10 * * **** ** 4 4 10 10
W2 after vaccination
0 10
14 21 28 Time (d)
7
0
B.1.351 2nd
80
100
40
60
W3 after vaccination
20
W6 after vaccination (W3 after second dose)
14 21 28 Time (d)
42
7
0
D614GB.1.1.7B.1.351
1 2 3 10 10 10 Serum dilution
4 10
0 0 10
0 0 10
35
42
B.1.1.7 2nd
35
14 21 Time (d)
28
D614G B.1.1.7B.1.351
4
D614G B.1.1.B7.1.351
0
7
D614G B.1.1.7 B.1.351
1 10
2 10
3 10
4 10
5 10
1st
3 10 50 ED2 10
D614GB. 1.1.B7.1.351
W2 after vaccination
4 10
5 10
D614G 2nd
1 2 3 10 10 10 Serum dilution
0 10
1 10
0 0 10
3 10
4 10
2 10
*
40
W2 after vaccination
100
ARTICLES
60
80
c
b
0 10
4 10
3 10 50 ED2 10
1 10
5 10
80
0 0 10
4 10
1 2 3 10 10 10 Serum dilution
100
20
40
60
Neutralizer (ED > 30) 50
D614G B.1.1.B7.1.351
W3 after vaccination
0 10
2 10
1 10
D614BG.1 .1.B7.1.351
35
12
8
42
16
38
63
W3 after vaccination
***
3 10
Nonneutralizer (ED < 30) 50
1st
Neu2t0ralization (%)
***
40
80
20
60
100
D614G B.1.1.B7.1.351
10
15
d
Fig. 4 |Sensitivity of SARS-CoV-2 D614G, B.1.1.7 and B.1.351 variants to sera from vaccine recipients.a, Examples of neutralization curves with sera from one donor (D9) at week 2 (W2), W3, W4 (W1 after second dose) and W6 (W3 after second dose) after vaccination. Results are shown as the mean±s.d. from three independent experiments.b, Neutralization ED50values of the three viral isolates. Sera from 10 to 16 vaccine recipients were sampled at W2 (n=15), W3 (n=16) and W1 and W3 after the second dose (n=10 and 15, respectively). Data are the mean from two to four independent experiments. The dotted line indicates an ED50of 30. Two-sided Friedman test with Dunn’s test for multiple comparisons was performed between each viral strain at the different time points; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. W2: D614G versus B.1.1.7,P=0.0105; D614G versus B.1.351,P=0.008. W3: D614G versus B.1.351,P=0.0002. W4: D614G versus B.1.351,P=0.011; B.1.1.7 versus B.1.351,P=0.0052. W6: D614G versus B.1.1.7,P=0.0324; D614G versus B.1.351,P=0.0324; B.1.1.7 versus B.1.351,P<0.0001.c, Evolution overtime of neutralizing antibody titers in 14 vaccine recipients. The arrows indicate the first and second doses of vaccines.d, Each individual was arbitrarily defined as a ‘neutralizer’ (blue) if neutralizing activity was detected at a 1:30 serum dilution or ‘non-neutralizer’ (gray) if no activity was detected. The numbers indicate the percentage of neutralizers.
0
5 33 No. of vaccinees 13 0
1 10
2 10
3 10
1st
0 10
5 10
4 10
W4 after vaccination W6 after vaccination (W1 after second dose) (W3 after second dose) 10 14 12 892 92 80 80 10 77 6 8 60 6 4 4 2 2 0 0